HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522

Dent RA, Cortes J, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Haiderali A, Jia L, Nguyen AM, Pan W, O'Shaughnessy J, Schmid P (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S600-S601

Conference Proceedings Title: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2022.07.170

Authors with CRIS profile

Involved external institutions

Champalimaud Foundation / Fundação Champalimaud Portugal (PT) Baylor University (BU) United States (USA) (US) Hokkaido Cancer Society Japan (JP) Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD) United States (USA) (US) Quirónsalud Spain (ES) Yale University United States (USA) (US) Sungkyunkwan University (SKKU) Korea, Republic of (KR) Queen Mary University of London United Kingdom (GB) National Cancer Centre Singapore (NCCS) Singapore (SG) Westmead Hospital Australia (AU) HELIOS Kliniken Germany (DE) Philipps-Universität Marburg Germany (DE) Karolinska Institute Sweden (SE) Klinikum der Universität München Germany (DE) University of Texas Southwestern Medical Center (UT Southwestern) United States (USA) (US) Kliniken Essen-Mitte Germany (DE)

How to cite

APA:

Dent, R.A., Cortes, J., Pusztai, L., Mcarthur, H.L., Kuemmel, S., Bergh, J.,... Schmid, P. (2022). HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522. In ANNALS OF ONCOLOGY (pp. S600-S601). AMSTERDAM: ELSEVIER.

MLA:

Dent, R. A., et al. "HRQoL with neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522." Proceedings of the Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) AMSTERDAM: ELSEVIER, 2022. S600-S601.

BibTeX: Download